(Q24651927)

English

Ustekinumab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

Europe PubMed Central

Ustekinumab (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Oya Cingoz

1

0 references

language of work or name

0 references

publication date

1 May 2009

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Monoclonal Antibodies

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

216-221

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726595

7 April 2017

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726595

7 April 2017

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726595

7 April 2017

Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726595

7 April 2017

Inflammatory bowel disease: clinical aspects and established and evolving therapies

1 reference

https://api.crossref.org/works/10.4161/MABS.1.3.8593

22 April 2017

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726595

28 September 2017

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726595

28 September 2017

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726595

28 September 2017

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726595

28 September 2017

Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8593

21 January 2018

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8593

21 January 2018

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8593

21 January 2018

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8593

21 January 2018

Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20069753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20069753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/20069753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of interleukin-12 in the pathogenesis of psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20069753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20069753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/MABS.1.3.8593

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

PubMed publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20069753%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24651927&oldid=1622990523"